Chiara Catelli, Miriana D'Alessandro, Federico Mathieu, Roberto Corzani, Marco Ghisalberti, Andrea Lloret Madrid, Susanna Guerrini, Piero Paladini, Luca Luzzi
{"title":"肺切除术的精确手术框架:机器人、视频辅助和开放节段切除术。","authors":"Chiara Catelli, Miriana D'Alessandro, Federico Mathieu, Roberto Corzani, Marco Ghisalberti, Andrea Lloret Madrid, Susanna Guerrini, Piero Paladini, Luca Luzzi","doi":"10.3390/jpm15080387","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> To evaluate outcomes of patients undergoing lung segmentectomy using open thoracotomy, Video-Assisted Thoracoscopic Surgery (VATS), or Robotic-Assisted Thoracoscopic Surgery (RATS) approaches. <b>Methods:</b> A total of 157 patients (mean age: 68.7 years; 58% male) who underwent lung segmentectomy from 2015 to 2024 at the Thoracic Surgery of Siena were retrospectively enrolled and divided into groups based on the surgical approach: thoracotomy (<i>n</i> = 60), VATS (<i>n</i> = 58), and RATS (<i>n</i> = 39). No significant differences were observed between groups in terms of age, gender, or tumor stage. Peri-operative outcomes, and, in patients with non-small cell lung cancer (NSCLC, <i>n</i> = 104), long-term outcomes, were analyzed. Group comparisons were conducted using Kruskal-Wallis, Dunn's test, Chi-squared, or Fisher's exact test and Kaplan-Meier analysis with log-rank test. <b>Results:</b> Conversion rate was 13% and 0% for VATS and RATS, respectively (<i>p</i> = 0.005). Pleural effusion on first post-operative day was lower in RATS than VATS (<i>p</i> = 0.0006) and open (<i>p</i> < 0.0001). The maximum Visual Analogue Scale (VAS) value recorded was lower in RATS than open (<i>p</i> = 0.016) and VATS (<i>p</i> = 0.013). Surgery time was longer for RATS than open (<i>p</i> = 0.001) and VATS (<i>p</i> = 0.013). No differences were found in hospital stay and post-operative complications. In patients with NSCLC, the median follow-up was 25 months. The 90-day mortality rate was 9.5% in thoracotomy, 0% in VATS and RATS (<i>p</i> = 0.05). The 1- and 2-year overall survival was higher in VATS and RATS groups than thoracotomy (<i>p</i> = 0.001 and <i>p</i> = 0.040, respectively). The number of harvested lymph nodes was larger in the open group (<i>p</i> = 0.010), while a higher number of stations were harvested in RATS and open than VATS (<i>p</i> = 0.001). No differences were found in local recurrence (<i>p</i>= 0.08). <b>Conclusions:</b> RATS segmentectomy ensures a lower conversion rate, less post-operative pain, reduced daily pleural effusion, and a greater number of harvested lymph node stations compared to VATS, providing comparable peri-operative outcomes. RATS and VATS segmentectomy offer an advantage over the open approach in short- and long-term survival.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 8","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387439/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Precision Surgery Framework for Lung Resection: Robotic, Video-Assisted, and Open Segmentectomy.\",\"authors\":\"Chiara Catelli, Miriana D'Alessandro, Federico Mathieu, Roberto Corzani, Marco Ghisalberti, Andrea Lloret Madrid, Susanna Guerrini, Piero Paladini, Luca Luzzi\",\"doi\":\"10.3390/jpm15080387\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives:</b> To evaluate outcomes of patients undergoing lung segmentectomy using open thoracotomy, Video-Assisted Thoracoscopic Surgery (VATS), or Robotic-Assisted Thoracoscopic Surgery (RATS) approaches. <b>Methods:</b> A total of 157 patients (mean age: 68.7 years; 58% male) who underwent lung segmentectomy from 2015 to 2024 at the Thoracic Surgery of Siena were retrospectively enrolled and divided into groups based on the surgical approach: thoracotomy (<i>n</i> = 60), VATS (<i>n</i> = 58), and RATS (<i>n</i> = 39). No significant differences were observed between groups in terms of age, gender, or tumor stage. Peri-operative outcomes, and, in patients with non-small cell lung cancer (NSCLC, <i>n</i> = 104), long-term outcomes, were analyzed. Group comparisons were conducted using Kruskal-Wallis, Dunn's test, Chi-squared, or Fisher's exact test and Kaplan-Meier analysis with log-rank test. <b>Results:</b> Conversion rate was 13% and 0% for VATS and RATS, respectively (<i>p</i> = 0.005). Pleural effusion on first post-operative day was lower in RATS than VATS (<i>p</i> = 0.0006) and open (<i>p</i> < 0.0001). The maximum Visual Analogue Scale (VAS) value recorded was lower in RATS than open (<i>p</i> = 0.016) and VATS (<i>p</i> = 0.013). Surgery time was longer for RATS than open (<i>p</i> = 0.001) and VATS (<i>p</i> = 0.013). No differences were found in hospital stay and post-operative complications. In patients with NSCLC, the median follow-up was 25 months. The 90-day mortality rate was 9.5% in thoracotomy, 0% in VATS and RATS (<i>p</i> = 0.05). The 1- and 2-year overall survival was higher in VATS and RATS groups than thoracotomy (<i>p</i> = 0.001 and <i>p</i> = 0.040, respectively). The number of harvested lymph nodes was larger in the open group (<i>p</i> = 0.010), while a higher number of stations were harvested in RATS and open than VATS (<i>p</i> = 0.001). No differences were found in local recurrence (<i>p</i>= 0.08). <b>Conclusions:</b> RATS segmentectomy ensures a lower conversion rate, less post-operative pain, reduced daily pleural effusion, and a greater number of harvested lymph node stations compared to VATS, providing comparable peri-operative outcomes. RATS and VATS segmentectomy offer an advantage over the open approach in short- and long-term survival.</p>\",\"PeriodicalId\":16722,\"journal\":{\"name\":\"Journal of Personalized Medicine\",\"volume\":\"15 8\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387439/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Personalized Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jpm15080387\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15080387","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
A Precision Surgery Framework for Lung Resection: Robotic, Video-Assisted, and Open Segmentectomy.
Objectives: To evaluate outcomes of patients undergoing lung segmentectomy using open thoracotomy, Video-Assisted Thoracoscopic Surgery (VATS), or Robotic-Assisted Thoracoscopic Surgery (RATS) approaches. Methods: A total of 157 patients (mean age: 68.7 years; 58% male) who underwent lung segmentectomy from 2015 to 2024 at the Thoracic Surgery of Siena were retrospectively enrolled and divided into groups based on the surgical approach: thoracotomy (n = 60), VATS (n = 58), and RATS (n = 39). No significant differences were observed between groups in terms of age, gender, or tumor stage. Peri-operative outcomes, and, in patients with non-small cell lung cancer (NSCLC, n = 104), long-term outcomes, were analyzed. Group comparisons were conducted using Kruskal-Wallis, Dunn's test, Chi-squared, or Fisher's exact test and Kaplan-Meier analysis with log-rank test. Results: Conversion rate was 13% and 0% for VATS and RATS, respectively (p = 0.005). Pleural effusion on first post-operative day was lower in RATS than VATS (p = 0.0006) and open (p < 0.0001). The maximum Visual Analogue Scale (VAS) value recorded was lower in RATS than open (p = 0.016) and VATS (p = 0.013). Surgery time was longer for RATS than open (p = 0.001) and VATS (p = 0.013). No differences were found in hospital stay and post-operative complications. In patients with NSCLC, the median follow-up was 25 months. The 90-day mortality rate was 9.5% in thoracotomy, 0% in VATS and RATS (p = 0.05). The 1- and 2-year overall survival was higher in VATS and RATS groups than thoracotomy (p = 0.001 and p = 0.040, respectively). The number of harvested lymph nodes was larger in the open group (p = 0.010), while a higher number of stations were harvested in RATS and open than VATS (p = 0.001). No differences were found in local recurrence (p= 0.08). Conclusions: RATS segmentectomy ensures a lower conversion rate, less post-operative pain, reduced daily pleural effusion, and a greater number of harvested lymph node stations compared to VATS, providing comparable peri-operative outcomes. RATS and VATS segmentectomy offer an advantage over the open approach in short- and long-term survival.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.